Vigil Neuroscience, Inc. (VIGL)
After hours:
| Previous close | 2.5800 |
| Open | 2.6200 |
| Bid | 2.6000 x 100 |
| Ask | 2.8100 x 100 |
| Day's range | 2.5000 - 2.7100 |
| 52-week range | 2.5000 - 11.1100 |
| Volume | |
| Avg. volume | 88,528 |
| Market cap | 101.853M |
| Beta (5Y monthly) | 1.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.75 |
GlobeNewswireVigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology - - Positive interim IGNITE Phase 2 data demonstrating iluzanebart (VGL101) as potential disease-modifying therapy for ALSP WATERTOWN, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today anno
- GlobeNewswire
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – – Enrollment for IGNITE trial completed with 20 patients enrolled; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer clinical trial evaluating VG-3927 ongoing; Interim data analysis on track for mid-2024 – – Appointed biotech industry executive Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer – WATERTOWN, Mass., March 26, 2024
Simply Wall St.Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
